fbpx

ADVERTISEMENT

ADVERTISEMENT

IgA Nephropathy

Updated : December 14, 2022



Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

 

sparsentan 

200 mg orally every Day initially; following 14 days, increase to advised dose of 400 mg every Day
When resuming, start with 200 mg/day and then gradually increase to 400 mg/day after 14 days



Dose Adjustments

Dosage Modifications
ALT/AST >3x to ≤8x ULN
Repeat observations to verify elevation
If confirmed, discontinue medication. Once levels return to pre-treatment values and the patient is asymptomatic, monitor ALT/AST levels, bilirubin levels, and INR at least once a week.
Coadministration of strong CYP3A4 inhibitors
Avoid from coadministration
In case usage cannot be avoided, interrupt sparsentan
Renal impairment
There were no clinically significant variations in the pharmacokinetics of mild-to-moderate (eGFR 30-89 mL/min/1.73 m2) patients.
Unstudied for severe (eGFR 30 mL/min/1.73 m2)
Hepatic impairment
(Child-Pugh A-C) Mild, moderate, or severe Avoid usage as there is a danger of severe liver damage if there is any hepatic impairment.
Dosing Considerations
Before initiating
Check that women who are sexually active are not pregnant and that they are taking effective contraception.
Assess ALT, AST, and bilirubin; avoid from initiating if >3x ULN
Aliskiren, endothelin receptor antagonists, and renin-angiotensin-aldosterone system (RAAS) inhibitors should not be used anymore.
Monitoring
Prior to starting therapy, ALT, AST, and bilirubin should be monitored. For the first 12 months, they should be checked every month.
Check on women who are sexually active every month while they are receiving therapy and for one month after they stop taking the drug.

 
 

Media Gallary

References

Octopus-Inspired Patches Might Be A Pain-Free Alternative to Injections
News
Octopus-Inspired Patches Might Be A Pain-Free Alternative to Injections
Posted on
Feminist Cancer Care Approach Aims to Save 800,000 Lives Annually
News
Feminist Cancer Care Approach Aims to Save 800,000 Lives Annually
Posted on
Breast Lifts Soar in Popularity Among Women
News
Breast Lifts Soar in Popularity Among Women
Posted on
Researchers Raise Concern on Alcohol Promotion in Sports
News
Researchers Raise Concern on Alcohol Promotion in Sports
Posted on

ADVERTISEMENT 

IgA Nephropathy

Updated : December 14, 2022


sparsentan 

200 mg orally every Day initially; following 14 days, increase to advised dose of 400 mg every Day
When resuming, start with 200 mg/day and then gradually increase to 400 mg/day after 14 days



Dose Adjustments

Dosage Modifications
ALT/AST >3x to ≤8x ULN
Repeat observations to verify elevation
If confirmed, discontinue medication. Once levels return to pre-treatment values and the patient is asymptomatic, monitor ALT/AST levels, bilirubin levels, and INR at least once a week.
Coadministration of strong CYP3A4 inhibitors
Avoid from coadministration
In case usage cannot be avoided, interrupt sparsentan
Renal impairment
There were no clinically significant variations in the pharmacokinetics of mild-to-moderate (eGFR 30-89 mL/min/1.73 m2) patients.
Unstudied for severe (eGFR 30 mL/min/1.73 m2)
Hepatic impairment
(Child-Pugh A-C) Mild, moderate, or severe Avoid usage as there is a danger of severe liver damage if there is any hepatic impairment.
Dosing Considerations
Before initiating
Check that women who are sexually active are not pregnant and that they are taking effective contraception.
Assess ALT, AST, and bilirubin; avoid from initiating if >3x ULN
Aliskiren, endothelin receptor antagonists, and renin-angiotensin-aldosterone system (RAAS) inhibitors should not be used anymore.
Monitoring
Prior to starting therapy, ALT, AST, and bilirubin should be monitored. For the first 12 months, they should be checked every month.
Check on women who are sexually active every month while they are receiving therapy and for one month after they stop taking the drug.

Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.

Facebook-f Twitter Instagram Youtube Linkedin Telegram

CONTACT INFORMATION

  • Telephone: 617-430-5616
  • General Inquiries: support@medtigo.com
  • State Licensing Services: Licensing@medtigo.com
  • Staffing Services: staffing@medtigo.com

ADDRESS

USA – BOSTON

60 Roberts Drive, Suite 313
North Adams, MA 01247

INDIA – PUNE

7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra

JOIN THE FASTEST GROWING HEALTHCARE COMMUNITY!

CREATE A NEW ACCOUNT

Download our APP

Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.

Facebook-f Twitter Instagram Youtube Linkedin Telegram

CONTACT INFORMATION

ADDRESS

MASSACHUSETTS – USA

60 Roberts Drive, Suite 313,
North Adams, MA 01247

MAHARASHTRA – INDIA

7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra

 

Taking the Pain out of Your Career

JOIN TODAY

DOWNLOAD APP

Free CME credits

Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.

Digital Certificate PDF

On course completion, you will receive a full-sized presentation quality digital certificate.

medtigo Simulation

A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.

medtigo Points

medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
 
  • Registration with medtigo = 10 points
  • 1 visit to medtigo’s website = 1 point
  • Interacting with medtigo posts (through comments/clinical cases etc.) = 5 points
  • Attempting a game = 1 point
  • Community Forum post/reply = 5 points

    *Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.

All Your Certificates in One Place

When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.

Our Certificate Courses

ACLS CERTIFICATION

  • 4.25 CME/CE Credits
  • Free ACLS Provider Card
  • 100% Online Training
  • Two Year Certification

BLS CERTIFICATION

  • 3 CME/CE Credits
  • Free BLS Provider Card
  • 100% Online Training
  • Two Year Certification

PALS CERTIFICATION

  • 4 CME/CE Credits
  • Free PALS Provider Card
  • 100% Online Training
  • Two Year Certification

NRP CERTIFICATION

  • 3 CME/CE Credits
  • Free NRP Provider Card
  • 100% Online Training
  • Two Year Certification